10-Q quarterly report · filed Nov 5, 2026

RIGEL PHARMACEUTICALS INC (RIGL) Q3 2026 10-Q Quarterly Report

Short answer

RIGEL PHARMACEUTICALS INC (RIGL) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $81M (up 16.5% year over year) with net income of $13M.

Q3 2026 key financials · XBRL

Revenue
$81M
+16.5% YoY · +2.8% QoQ
Net income
$13M
−52.7% YoY · −23.7% QoQ
Operating margin
21.1%
EPS (diluted)
$0.65
−55.8% YoY · −26.1% QoQ

Source: XBRL data from the RIGEL PHARMACEUTICALS INC (RIGL) Q3 2026 10-Q on SEC EDGAR. USD.

RIGEL PHARMACEUTICALS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $80.9M, up $11.4M YoY from $69.5M
  • Product sales $72.3M, up $8.2M YoY, led by TAVALISSE at $46.0M
  • Best performer: REZLIDHIA $9.9M, up 20% YoY; worst: GAVRETO $9.8M, down 11%
  • Operating cash flow $67.9M through nine months, versus $53.7M YoY; cash and investments $99.3M
  • Outlook: product sales expected to increase with VEPPANU launch, offset by rebate, reimbursement and competitive risks

Risk Factors

  • New VEPPANU transition risk, triggered by June 11, 2026 license effectiveness and August 13 launch, includes $40.0 million development funding cap
  • Most material operational update: Pfizer supply agreement carries $24.8 million estimated minimum-purchase obligation through 2030
  • Regulatory risk: CMS’s GLOBE Model final rule starts April 1, 2027, requiring rebates tied to international drug prices
  • Competitive risk: Annora’s generic fostamatinib approved June 2026, with sales licensed to begin second quarter 2032
  • Financial risk: MidCap revolving facility had $8.0 million outstanding at September 30, 2026, with variable SOFR-based interest

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other RIGEL PHARMACEUTICALS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.